Datwyler Holding Inc (Datwyler) is primarily engaged in the production of high-quality, system-critical elastomer components. The company holds leading positions in global markets such as healthcare, mobility, connectivity, general industry, and food and beverage. Datwyler operates a worldwide network of highly automated production facilities, enabling it to supply locally manufactured components to global pharmaceutical companies in key economic regions. The company operates through 25 sites across four continents and delivers components to over 1000 customers in more than 100 countries across Europe, North and South America, and Asia, with the Healthcare division also serving Australia.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Datwyler's has strategically positioned its R&D activities to enhance its market offerings and maintain competitive advantages. The company operates R&D centers near customers, ensuring close collaboration and innovation alignment. The company's R&D efforts focus on developing high-value components, particularly in the healthcare sector, where it supplies system-critical elastomer components for injectable drug delivery systems. The company emphasizes material expertise and solution design, which are central to its strategy of creating added value for customers. The company has also been involved in co-engineering projects, reflecting a robust pipeline of innovative products. In FY2025, the company spent CHF43.5 million on its R&D activities, which is 3.95% of its revenue and grew 2.11% YoY.